All stock lists
Guardant Health, Inc. (NASDAQ:GH)
US · Delayed Price · Currency is USD
Healthcare · Medical - Diagnostics & Research
174.64+5.56 (+3.29%)
Insider Score
––Not scored
GH Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
GH analyst forecast
GH analyst consensus
Moderate Buy12 ratings
Buy 12 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
GH 12-month price target
$210.00+20.5% upsideaverage of 3 firms
$220.00High
$200.00Low
Best analysts covering GH
- Guggenheim100%success rate · 4 calls
- Barclays100%success rate · 3 calls
- UBS100%success rate · 3 calls
- Stifel100%success rate · 3 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
GH analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| Morgan Stanley | Overweight | $200.00 | +22.7% | Reiterated | 2026-10-13 | |
| Barclays | Overweight | $220.00 | +28.9% | Reiterated | 2026-10-07 | |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-10-01 |
| Bernstein | — | $210.00 | +30.2% | — | 2026-09-10 | |
| — | UBS | Buy | — | — | Reiterated | 2026-09-09 |
| — | BTIG | Buy | — | — | Reiterated | 2026-09-02 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2026-08-04 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-08-04 |
| — | Stephens & Co. | Overweight | — | — | Reiterated | 2026-08-04 |
| — | Stifel | Buy | — | — | Reiterated | 2026-08-03 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2026-07-31 |
| — | BTIG | Buy | — | — | Reiterated | 2026-07-31 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-07-31 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-07-31 |
| — | Mizuho | Outperform | — | — | Reiterated | 2026-07-31 |
| — | TD Cowen | Buy | — | — | Reiterated | 2026-07-31 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-07-16 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2026-07-14 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-07-09 |
| — | Citigroup | Buy | — | — | Reiterated | 2026-07-08 |
| — | B of A Securities | Buy | — | — | Reiterated | 2026-07-06 |
| — | Evercore ISI Group | Outperform | — | — | Reiterated | 2026-07-06 |
| — | Bernstein | Outperform | — | — | Reiterated | 2026-07-02 |
| — | BTIG | Buy | — | — | Reiterated | 2026-07-01 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-06-29 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-06-24 |
| — | Mizuho | Outperform | — | — | Reiterated | 2026-06-08 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2026-06-05 |
| — | Evercore ISI Group | Outperform | — | — | Upgraded | 2026-06-02 |
| — | BTIG | Buy | — | — | Reiterated | 2026-05-27 |
| — | BTIG | Buy | — | — | Reiterated | 2026-05-26 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-05-08 |
| — | Evercore ISI Group | In Line | — | — | Reiterated | 2026-05-08 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2026-05-08 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-04-14 |
| — | Evercore ISI Group | In Line | — | — | Reiterated | 2026-04-06 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2026-02-24 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2026-02-20 |
| — | Leerink Partners | Outperform | — | — | Reiterated | 2026-02-20 |
| — | Citigroup | Buy | — | — | Reiterated | 2026-02-20 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2026-02-20 |
| — | TD Cowen | Buy | — | — | Reiterated | 2026-02-20 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-02-20 |
| — | Stifel | Buy | — | — | Reiterated | 2026-02-20 |
| — | Evercore ISI Group | In Line | — | — | Reiterated | 2026-02-20 |
| — | BTIG | Buy | — | — | Reiterated | 2026-02-20 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-01-26 |
| — | Stifel | Buy | — | — | Reiterated | 2026-01-09 |
| — | Evercore ISI Group | In Line | — | — | Downgraded | 2026-01-05 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-01-05 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2025-12-22 |
| — | Mizuho | Outperform | — | — | Reiterated | 2025-12-17 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-12-15 |
| — | Leerink Partners | Outperform | — | — | Reiterated | 2025-12-15 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2025-12-15 |
| — | Barclays | Overweight | — | — | Reiterated | 2025-12-15 |
| — | BTIG | Buy | — | — | Reiterated | 2025-12-12 |
| — | Citigroup | Buy | — | — | Reiterated | 2025-12-11 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2025-12-02 |
GH earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-19 | -0.77 | -1.00 | $272.4M | $281.3M |
| 2026-05-07 | -0.81 | -0.85 | $279.2M | $301.7M |
| 2026-07-30 | -0.76 | -0.90 | $314.2M | $335.0M |
| 2026-11-05 | -0.75 | 0.00 | $350.7M | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.